Gene therapy adds a working gene; gene editing rewrites the one you have. A plain-language guide to how each works, what is already approved, what they cost, and the risks that still limit them.
Adding paricalcitol, a prescription vitamin D analog, to standard chemotherapy raised the tumor response rate from 9% to 42% in 36 patients. It works not on the cancer cells but on the scar-like shield around them.
ai3Bio, formed from two startups and backed with $48 million, is developing an mRNA treatment that tells inflammatory Th17 cells to self-destruct. It is early — animal data only — but it targets a different culprit from most “immune reset” efforts.
It is one of the most common autoimmune diseases, and one of the slowest to be diagnosed. A plain-language guide to what Sjögren’s is, how it is found, how it is managed today, and the new drugs in late-stage trials.
People with higher blood levels of imidazole propionate, which gut microbes make from a common amino acid, showed more Alzheimer’s-related brain changes and faster cognitive decline. In mice, the molecule worsened the disease directly.
The Swiss drugmaker is paying China’s Abogen $575 million upfront for an injected mRNA that makes a B-cell-killing T-cell engager inside the patient — a possible simpler route to the “immune reset” that CAR-T promised for autoimmune disease.
The Autus valve can be widened with a balloon catheter as a child grows, from toddler size to adult size — sparing some children born with heart defects from repeated open-heart surgeries.
CAR-T turns a patient’s own immune cells into a living drug. It has transformed some blood cancers and is now being tested in lupus and multiple sclerosis. A plain-language guide to the process, the risks and what comes next.
From rheumatoid arthritis to eczema and alopecia, JAK inhibitors are among the most versatile drugs in immunology. A plain-language guide to how they work, the main ones, and why they carry a boxed warning.
With the $18 billion allergy and eczema blockbuster losing patent protection in 2031, the partners are betting on four long-acting antibodies that hit the same pathways with far fewer injections.
Bristol Myers Squibb’s heart drug becomes the first of its class approved for adolescents with the inherited condition, a leading cause of sudden cardiac death in young people.
The deal, worth up to $2.6 billion, gives Novo an early-stage oral GLP-1/GIP drug designed to be taken once a week — a bid to leapfrog today’s daily pills as its rivalry with Lilly intensifies.